source
- FDA accepts supplemental NDA for taletrectinib targeting ROS1‑positive lung cancerThe U.S. Food and Drug Administration has accepted a supplemental New Drug Application for taletrectinib, a targeted therapy aimed at patients with ROS1‑positive non‑small cell lung cancer. The fi…
- Experts highlight lack of reliable biomarkers for melanoma immunotherapy responseDr. Mario Sznol, a professor of clinical medical oncology at the University of Miami, discussed the ongoing difficulty of predicting which patients with metastatic melanoma will benefit from immune…